Xenios Advances Novel i-cor Synchronized Cardiac-Assist System In Europe
Xenios announced in late November that it had received CE mark for i-cor, an acute mechanical circulatory support device that provides assistance to a failing heart with an external, heartbeat-synchronized system that generates an artificial pulse. The company believes i-cor will open up new therapy options for the hundreds of thousands of patients in acute heart failure (cardiogenic shock) and in those undergoing high-risk interventions in the cath lab – a market opportunity estimated at $5 billion annually in the US and Europe alone.
You may also be interested in...
Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.